Ron Leuty
@rleutybiotech.bsky.social
Biotech reporter, San Francisco Business Times
Reposted by Ron Leuty
I spoke to CNN about how demoralizing it was to watch Stanford leadership stay silent while contrarians on campus launched unscientific attacks to stifle Stanford researchers. Now, those attacks have gone nationwide and much of MAHA leadership have ties to Stanford.
www.cnn.com/2025/11/08/p...
www.cnn.com/2025/11/08/p...
The Trump-MAHA-Stanford nexus of US health policy | CNN Politics
In early 2022, Stanford medical student Santiago Sanchez set out to organize a campus debate with Jay Bhattacharya — a professor at the university whose outspoken denunciations of pandemic lockdowns m...
www.cnn.com
November 10, 2025 at 5:52 PM
I spoke to CNN about how demoralizing it was to watch Stanford leadership stay silent while contrarians on campus launched unscientific attacks to stifle Stanford researchers. Now, those attacks have gone nationwide and much of MAHA leadership have ties to Stanford.
www.cnn.com/2025/11/08/p...
www.cnn.com/2025/11/08/p...
"Our technology has the potential to truly enable the delivery of a breadth of siRNA therapeutic opportunities to all patient populations." www.bizjournals.com/sanfrancisco...
Codexis switches CEOs as it lays off workers and grabs manufacturing space in East Bay - San Francisco Business Times
Here's why a Peninsula biotech switched CEOs, cut jobs and took new space in Hayward.
www.bizjournals.com
November 10, 2025 at 11:06 PM
"Our technology has the potential to truly enable the delivery of a breadth of siRNA therapeutic opportunities to all patient populations." www.bizjournals.com/sanfrancisco...
Reposted by Ron Leuty
Step 1: Make things more expensive by taxing them
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Trump: "We're gonna issue a dividend to our middle income people and lower income people of about $2,000, and we're gonna use the remaining tariffs to lower our debt."
November 10, 2025 at 9:05 PM
Step 1: Make things more expensive by taxing them
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Adverum warned in August of its desperate need for cash. It turns out it was already was deep in talks with Lilly at that time, but on a licensing deal, not a buyout. Then a loan. www.bizjournals.com/sanfrancisco...
How Adverum and its pioneering gene therapy ended up in a buyout by drug giant Lilly - San Francisco Business Times
Here’s exactly how Adverum and its pioneering gene therapy ended up in an unusual deal with Lilly.
www.bizjournals.com
November 10, 2025 at 3:49 PM
Adverum warned in August of its desperate need for cash. It turns out it was already was deep in talks with Lilly at that time, but on a licensing deal, not a buyout. Then a loan. www.bizjournals.com/sanfrancisco...
Kezar Life Sciences to lay off 70% amid FDA setback - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Kezar Life Sciences to lay off 70% of workforce as dispute with FDA apparently continues - San Francisco Business Times
Kezar Life Sciences to cut 70% of jobs in restructuring
www.bizjournals.com
November 10, 2025 at 3:43 PM
Kezar Life Sciences to lay off 70% amid FDA setback - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Denali Therapeutics' Carole Ho leaves for Lilly neuroscience job - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscience - San Francisco Business Times
Key Denali Therapeutics exec exits to head Lilly's neuroscience unit
www.bizjournals.com
November 7, 2025 at 12:15 AM
Denali Therapeutics' Carole Ho leaves for Lilly neuroscience job - San Francisco Business Times www.bizjournals.com/sanfrancisco...
'We jumped all over it': How drug maker Evommune seized on the federal shutdown to nail a $150 million IPO www.bizjournals.com/sanfrancisco...
'We jumped all over it': How drug maker Evommune took advantage of the federal shutdown to nail a $150 million IPO - San Francisco Business Times
For this Bay Area company, the government shutdown created an opportunity. "We jumped all over" the chance to go public, the CEO told the Business Times.
www.bizjournals.com
November 6, 2025 at 10:51 PM
'We jumped all over it': How drug maker Evommune seized on the federal shutdown to nail a $150 million IPO www.bizjournals.com/sanfrancisco...
BillionToOne stands out among biotech IPOs — first, the diagnostic test company has revenue; second, first-day trading popped www.bizjournals.com/sanfrancisco...
BillionToOne IPO becomes $5 billion explosion as Bay Area medical test maker's stock soars in debut - San Francisco Business Times
BillionToOne? More like $5 billion.
www.bizjournals.com
November 6, 2025 at 9:39 PM
BillionToOne stands out among biotech IPOs — first, the diagnostic test company has revenue; second, first-day trading popped www.bizjournals.com/sanfrancisco...
BillionToOne stands out among biotech IPOs — first, the diagnostic test company has revenue; second, first-day trading popped www.bizjournals.com/sanfrancisco...
BillionToOne IPO becomes $5 billion explosion as Bay Area medical test maker's stock soars in debut - San Francisco Business Times
BillionToOne? More like $5 billion.
www.bizjournals.com
November 6, 2025 at 9:37 PM
BillionToOne stands out among biotech IPOs — first, the diagnostic test company has revenue; second, first-day trading popped www.bizjournals.com/sanfrancisco...
RFK Jr. stopped a Covid vaccine trial. Bay Area biotechs may save it - San Francisco Business Times www.bizjournals.com/sanfrancisco...
RFK Jr. stopped Vaxart's oral Covid-19 vaccine trial. Now, a new partnership could save it - San Francisco Business Times
RFK Jr. stopped Vaxart's work on an oral Covid-19 vaccine. Now the company has a new partner in Dynavax
www.bizjournals.com
November 6, 2025 at 4:47 AM
RFK Jr. stopped a Covid vaccine trial. Bay Area biotechs may save it - San Francisco Business Times www.bizjournals.com/sanfrancisco...
"We're in a place here with this program where it has the potential to move forward the standard of care." — Braveheart Bio CEO Travis Murdoch www.bizjournals.com/sanfrancisco...
$185 million, proven team lead startup Braveheart Bio's toward late-stage heart drug trial - San Francisco Business Times
Biogen CEO Chris Viehbacher and Travis Murdoch — fellow Canadians — hit it off when Biogen last year bought Murdoch's HI-Bio for $1 billion. Now they're teaming up on heart-focused Braveheart Bio, bac...
www.bizjournals.com
November 5, 2025 at 5:22 PM
"We're in a place here with this program where it has the potential to move forward the standard of care." — Braveheart Bio CEO Travis Murdoch www.bizjournals.com/sanfrancisco...
Why Jennifer Doudna, Reed Jobs and others are backing this East Bay biotech aimed at cancer and chronic autoimmune diseases www.bizjournals.com/sanfrancisco...
Why Jennifer Doudna, Reed Jobs and others are backing this East Bay biotech's in-body cell fix-it shop - San Francisco Business Times
Jennifer Doudna. Reed Jobs' Yosemite Ventures. Third Rock Ventures. CAR-T. CRISPR. Gladstone. Parker Institute. UCSF. UC Berkeley. Stanford. Startup Azalea Therapeutics' got it all — including a fresh...
www.bizjournals.com
November 4, 2025 at 4:19 PM
Why Jennifer Doudna, Reed Jobs and others are backing this East Bay biotech aimed at cancer and chronic autoimmune diseases www.bizjournals.com/sanfrancisco...
Reposted by Ron Leuty
SCOOP: Idaho’s health department quietly declined the entirety of its annual $1.5 million federal Title X funding in April, leaving patients statewide without any access to the family planning program.
One Idaho health district no longer offers contraception at all.
From me:
One Idaho health district no longer offers contraception at all.
From me:
While some states fight to restore Title X family planning funding, Idaho chooses to forfeit it
The Idaho Department of Health and Welfare quietly declined the entirety of its annual $1.5 million federal Title X funding, leaving patients statewide without free and low-cost contraception and repr...
www.newsfromthestates.com
November 3, 2025 at 9:13 PM
SCOOP: Idaho’s health department quietly declined the entirety of its annual $1.5 million federal Title X funding in April, leaving patients statewide without any access to the family planning program.
One Idaho health district no longer offers contraception at all.
From me:
One Idaho health district no longer offers contraception at all.
From me:
How Cellares became the Bay Area's fastest-growing private company - San Francisco Business Times www.bizjournals.com/sanfrancisco...
How Cellares became the Bay Area's fastest-growing startup - San Francisco Business Times
Our annual Fastest-Growing Private Companies tabulation has a company whose CEO wants to make sure "patients don't have to die on the waiting list anymore."
www.bizjournals.com
November 3, 2025 at 2:26 PM
How Cellares became the Bay Area's fastest-growing private company - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Fatty liver and fatter wallets: Investment banks, some execs and select board members will get payouts from Roche's buyout of 89bio and Novo Nordisk's deal with Akero - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Fatty liver disease companies' multibillion-dollar deals mean fatter wallets - San Francisco Business Times
Investment banks and executives will reap over $150 million in fees from two major Bay Area biotech deals.
www.bizjournals.com
October 31, 2025 at 3:41 PM
Fatty liver and fatter wallets: Investment banks, some execs and select board members will get payouts from Roche's buyout of 89bio and Novo Nordisk's deal with Akero - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Drug developer Evommune sets date, not price, of shutdown-era IPO - San Francisco Business Times
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Drug developer Evommune to go public next week, following MapLight's successful IPO - San Francisco Business Times
Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.
www.bizjournals.com
October 31, 2025 at 1:46 AM
Drug developer Evommune sets date, not price, of shutdown-era IPO - San Francisco Business Times
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Why this SoCal biotech is setting up shop at Kilroy's big Oyster Point campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - San Francisco Business Times
A San Diego biotech is leaving room to grow at Kilroy's big South City development.
www.bizjournals.com
October 30, 2025 at 9:24 PM
Why this SoCal biotech is setting up shop at Kilroy's big Oyster Point campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
BridgeBio will file next year for FDA approval of the drug, which was discovered by Japan Tobacco and was once controlled by Merck
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
BridgeBio lands another rare disease drug trial, seeks FDA approval - San Francisco Business Times
Once controlled by Merck, this drug now is headed toward an FDA decision under BridgeBio.
www.bizjournals.com
October 29, 2025 at 8:44 PM
BridgeBio will file next year for FDA approval of the drug, which was discovered by Japan Tobacco and was once controlled by Merck
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
AI isn't just for tech. Here's what that means for one landlord - San Francisco Business Times www.bizjournals.com/sanfrancisco...
AI isn't just for tech. Here's what that means for one landlord - San Francisco Business Times
What AI tenants are looking for may surprise you, this landlord says.
www.bizjournals.com
October 29, 2025 at 7:07 PM
AI isn't just for tech. Here's what that means for one landlord - San Francisco Business Times www.bizjournals.com/sanfrancisco...
One of the Bay Area's big biotech landlords sold a 30% stake of South SF campus to a sovereign wealth fund and created a joint venture three years ago. Now it's taking a big writedown on the property. - San Francisco Business Times www.bizjournals.com/sanfrancisco...
What Healthpeak Properties' big write-down on a South San Francisco campus signals - San Francisco Business Times
The impairment charge on Healthpeak's longtime South San Francisco property reflects shifting dynamics in the Bay Area's biotech real estate market.
www.bizjournals.com
October 29, 2025 at 3:41 PM
One of the Bay Area's big biotech landlords sold a 30% stake of South SF campus to a sovereign wealth fund and created a joint venture three years ago. Now it's taking a big writedown on the property. - San Francisco Business Times www.bizjournals.com/sanfrancisco...
BioMarin looked at 2023 as the 'year of Roctavian' -- the hemophilia A gene therapy -- but now it's looking to divest it - San Francisco Business Times www.bizjournals.com/sanfrancisco...
BioMarin loved its one-shot-and-done fix for hemophilia A when it was approved. But now it's looking to sell it - San Francisco Business Times
Lauded as a one-shot-and-done fix for hemophilia A patients, BioMarin is now kicking this gene therapy to the curb.
www.bizjournals.com
October 29, 2025 at 3:34 PM
BioMarin looked at 2023 as the 'year of Roctavian' -- the hemophilia A gene therapy -- but now it's looking to divest it - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Genentech to cut 118 jobs, including data scientist roles - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Biotech pioneer Genentech to lay off more than 100 workers, including data scientists and executives - San Francisco Business Times
Here are the latest Genentech employees facing layoffs.
www.bizjournals.com
October 29, 2025 at 3:28 PM
Genentech to cut 118 jobs, including data scientist roles - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Why a big biotech landlord took a big write-down on the value of a Peninsula site - San Francisco Business Times www.bizjournals.com/sanfrancisco...
What Healthpeak Properties' big write-down on a South San Francisco campus signals - San Francisco Business Times
The impairment charge on Healthpeak's longtime South San Francisco property reflects shifting dynamics in the Bay Area's biotech real estate market.
www.bizjournals.com
October 28, 2025 at 11:13 PM
Why a big biotech landlord took a big write-down on the value of a Peninsula site - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Here's why BridgeBio's potential drug for limb-girdle muscular dystrophy is important to the company and the family of former Bank of America Chairman and CEO Hugh McColl Jr.
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
BridgeBio's stock soars after stunning early data against a deadly rare disease - San Francisco Business Times
How former BofA CEO Hugh McColl's family played a role in developing a drug for a deadly rare disease.
www.bizjournals.com
October 28, 2025 at 2:19 PM
Here's why BridgeBio's potential drug for limb-girdle muscular dystrophy is important to the company and the family of former Bank of America Chairman and CEO Hugh McColl Jr.
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Akero's rocky road to $5.2 billion buyout: Novo walked away, a late-stage misunderstanding, a switch in law firms, leaks and a lingering, unique shareholder complaint www.bizjournals.com/sanfrancisco...
How Akero Therapeutics saved a multibillion-dollar biotech deal - San Francisco Business Times
Akero Therapeutics CEO Andrew Cheng saved his company’s multibillion-dollar biotech deal with Novo Nordisk when it appeared to fall apart. Here’s how he did it.
www.bizjournals.com
October 27, 2025 at 1:21 PM
Akero's rocky road to $5.2 billion buyout: Novo walked away, a late-stage misunderstanding, a switch in law firms, leaks and a lingering, unique shareholder complaint www.bizjournals.com/sanfrancisco...